KT-621

KT-621 is an investigational, first-in-class, once-daily oral small molecule degrader of STAT6, a transcription factor that mediates IL-4/IL-13 signaling and is a central driver of Th2 inflammation. Developed by Kymera Therapeutics using targeted protein degradation technology, KT-621 works by flagging STAT6 for intracellular degradation, thereby blocking the downstream effects of type 2 inflammatory pathways. Preclinical and early clinical data show that KT-621 achieves robust STAT6 degradation in blood and skin with dupilumab-like activity in models of atopic dermatitis (AD) and asthma. The drug aims to provide biologic-like efficacy with the convenience of oral administration for diseases driven by Th2 inflammation—including AD, asthma, chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), among others[1][3][5][7][9].